Positioning no disclosures inside 60 days, left as found
Options put/call open interest 1.25, read 2026-10-28
Ethical does not pass the values gate
Price39.31 USD
Fair value53.00
Ethical score70.0/100
Our investment reviews on this name
2026-10-02Read Markdown44.64-11.9% to today ✓Markup gives way to Markdown after a 28% rise in 13 weeks
2026-07-02Read Markup34.83+12.9% to today ✓First review on file: Markup
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Edgewise Therapeutics, Inc. holds its Markdown at $39.31. The statistical read favours the sellers, held for 34 days.
As held on the ledger · 2026-10-23
Phase
Markdown · caution
Quantitative state
The statistical read favours the sellers, held for 34 days
Price at the screen
$39.31
Valuation
N/A trailing · -22.41 forward price to earnings
Values screen
FAIL· score 70.0
Beta
0.36
The Workings
Five Screens, Shown in Full
Does not pass. Interest-bearing securities
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
0.72%
Below 33%
Interest-bearing debt is just 0.7% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
84.86%
Below 33%
Interest-bearing cash and securities are 84.9% of assets, above the one-third limit.
Fail
Receivables
11.07%
Below 49%
Money owed to the company is 11.1% of assets, under the 49% limit.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
Edgewise Therapeutics,'s business is fine, but its cash and interest-bearing securities are about 85% of its assets, well over the ~33% line, so it does not pass on the financial screens.
Read as at 2026-10-28. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when EWTX's ethical verdict changes
Today EWTX does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
Fair value range in USD, drawn from the 2026-10-23 screen. The gold marker is the market price at the same screen. A 34.8% margin of safety to the base estimate.
Third-party analyst targets: 13 covering, consensus Strong Buy. The average target sits +35% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-10-23 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Biotech Muscle Drug Developer Lacks Ethical Data
A patient with a rare muscle disorder waits years for any new pill that might slow the damage. Edgewise is one of several small biotechs chasing that hope with an oral candidate now in mid-stage trials, yet we pass. The ethical screen returns insufficient data because standard financial ratios are missing, and that single gap is enough to keep the name off any list we would consider.
The reported numbers tell a familiar pre-revenue story. Forward earnings sit at minus 26 times, profit margins are zero, and return on equity is minus 38 percent. Thirteen analysts still cluster around a 52 dollar median target, but those forecasts rest entirely on future trial success rather than any current cash generation or competitive edge.
Clinical failure rates in this field remain high, dilution risk is constant, and the absence of basic ratio data blocks any proper ethical review. We therefore stay away until clearer financial and governance information appears. Analysis, not advice.
The risks · The things to watch: as a biotechnology name, trial and regulatory outcomes can move it sharply either way.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
EWTX trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-10-28Markdown$39.75+0.0%Entry 9
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 17% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 114%. Our forward projection puts the odds of a 10% gain over the next month near 37%. The street (12 analysts) rates it buy, with a mean price target of $44. Insiders have been net sellers over the past quarter.
2026-10-21Markdown$39.75+1.3%Entry 8
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 1.3% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D. Technically it is holding around 12% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 114%. Our forward projection puts the odds of a 10% gain over the next month near 37%. The street (12 analysts) rates it buy, with a mean price target of $44. Insiders have been net sellers over the past quarter.
2026-10-14Markdown$39.25-12.1%Entry 7
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 12.1% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 36% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 114%. Our forward projection puts the odds of a 10% gain over the next month near 37%. The street (12 analysts) rates it buy, with a mean price target of $44. Insiders have been net sellers over the past quarter.
2026-10-02Markdown · changed$44.64+0.6%Entry 6
The framework has shifted from markup to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 0.6% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 36% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 114%. Our forward projection puts the odds of a 10% gain over the next month near 37%. The street (12 analysts) rates it buy, with a mean price target of $44. Insiders have been net sellers over the past quarter.
2026-08-28Markup$44.38+11.6%Entry 5
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 11.6% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 36% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 114%. Our forward projection puts the odds of a 10% gain over the next month near 37%. The street (12 analysts) rates it buy, with a mean price target of $44. Insiders have been net sellers over the past quarter.
2026-07-28Markup$39.76+14.2%Entry 4
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 14.2% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 36% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 114%. Our forward projection puts the odds of a 10% gain over the next month near 37%. The street (12 analysts) rates it buy, with a mean price target of $44.
2026-07-18Markup$34.83+0.0%Entry 3
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 36% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 114%. Our forward projection puts the odds of a 10% gain over the next month near 37%. The street (12 analysts) rates it buy, with a mean price target of $44.
2026-07-03Markup$34.83+0.0%Entry 2
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns.
2026-07-02Markup$34.83Entry 1
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
